Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Meier, Reinhard ^a   Braren, Rickmer ^a   Kosanke, Yvonne ^a   Bussemer, Johanna ^a   Neff, Frauke ^b   Wildgruber, Moritz ^a   Schwarzenböck, Sarah ^a   Frank, Annette ^a   Haller, Bernhard ^c   Hohlbaum, Andreas M ^d   Schwaiger, Markus ^a   Gille, Hendrik ^d   Rummeny, Ernst J ^a   Beer, Ambros J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Pieris Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; PRS 050 POLYETHYLENE GLYCOL 40; UNCLASSIFIED DRUG; ANGIOCAL PROTEIN; LIPOCALIN; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALIPER; CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; HISTOPATHOLOGY; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MOUSE; NECROPTOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RHABDOMYOSARCOMA; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME; ANIMAL; DIAGNOSTIC USE; MULTIMODAL IMAGING; NEOVASCULARIZATION, PATHOLOGIC; SCINTISCANNING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORODEOXYGLUCOSE F18; LIPOCALINS; MAGNETIC RESONANCE IMAGING; MICE; MULTIMODAL IMAGING; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84900454941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094972     Document Type: Article

References (44)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
2. Kane RC, Farrell AT, Saber H, Tang S, Williams G, et al. (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278. (Pubitemid 46095398)
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. (Pubitemid 38702844)
5. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60: 203-212. (Pubitemid 30070735)
6. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. 10.1038/nm0603-669 [doi];nm0603-669 [pii].
7. Landgren E, Schiller P, Cao Y, Claesson-Welsh L (1998) Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 16: 359-367. (Pubitemid 28052290)
8. D'Angelo G, Struman I, Martial J, Weiner RI (1995) Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci U S A 92: 6374-6378.
9. Nor JE, Christensen J, Mooney DJ, Polverini PJ (1999) Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154: 375-384. (Pubitemid 29094088)
10. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395.
11. Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A (2005) Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 54: 53-61. (Pubitemid 40387005)
12. Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6: 349-356. (Pubitemid 46696550)
13. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300: 2277-2285. 300/19/2277 [pii];10.1001/jama.2008.656 [doi].
14. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, et al. (2009) Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 7: 171-181. JTH3212 [pii];10.1111/j.1538-7836. 2008.03212.x [doi].
15. Kothari M, Guermazi A, White D, Suhy J, Reinhold C (2003) Imaging in antiangiogenesis trial: a clinical trials radiology perspective. Br J Radiol 76 Spec No 1: S92-S96. (Pubitemid 39530321)
16. Skerra A (2008) Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J 275: 2677-2683.
17. Gille H, Huelmeyer M, Christian HJ, Matschiner G, Trentmann S, et al (2008) Discovery and characterization of a novel Anticalin with potent in vivo antagonistic activity towards VEGF-A.
18. Braren R, Curcic J, Remmele S, Altomonte J, Ebert O, et al. (2011) Free-Breathing Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in a Rat Liver Tumor Model Using Dynamic Radial T1 Mapping. Invest Radiol.
19. Braren R, Altomonte J, Settles M, Neff F, Esposito I, et al. (2011) Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. J Hepatol.
20. Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, et al. (2008) Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 48: 1864-1873.
21. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, et al. (2000) Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 44: 563-574.
22. Galluzzi L, Kroemer G (2008) Necroptosis: a specialized pathway of programmed necrosis. Cell 135: 1161-1163. S0092-8674(08)01565-1 [pii];10.1016/j.cell.2008.12.004 [doi].
23. Mross K, Fischer R, Richly H, Scharr D, Buechert M, Stern A, Hoth D, Gille H, Audoly LP, Scheulen ME (2011) First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study. Mol Cancer Ther 10.
24. Tortora G, Melisi D, Ciardiello F (2004) Angiogenesis: a target for cancer therapy. Curr Pharm Des 10: 11-26. (Pubitemid 38072740)
25. Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50 Suppl 1: 1S-10S. jnumed.108.057174 [pii];10.2967/jnumed.108.057174 [doi].
26. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, et al. (2004) 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101: 1776-1785. 10.1002/cncr.20585 [doi]. (Pubitemid 39314740)
27. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, et al. (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106: 1376-1381. 2005-01-0272 [pii];10.1182/blood-2005-01-0272 [doi].
28. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van TH, et al. (2005) Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy- D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23: 8362-8370. 23/33/8362 [pii];10.1200/JCO.2005.01.1189 [doi].
29. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50 Suppl 1: 43S-54S. 50/Suppl-1/43S [pii];10.2967/jnumed.108.057224 [doi].
30. Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188: 1622-1635. 188/6/1622 [pii];10.2214/AJR.06.1403 [doi].
31. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, et al. (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11: 102-125.
32. Thoeny HC, De KF, Chen F, Vandecaveye V, Verbeken EK, et al. (2005) Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7: 779-787.
33. Thoeny HC, De KF, Chen F, Ni Y, Landuyt W, et al. (2005) Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234: 756-764. 234/3/756 [pii];10.1148/radiol.2343031721 [doi].
34. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, et al. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92: 1599-1610. 6602550 [pii];10.1038/sj.bjc.6602550 [doi].
35. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, et al. (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24: 769-777. JCO.2005.03.4645 [pii];10.1200/JCO.2005.03.4645 [doi].
36. O'Connor JP, Jackson A, Parker GJ, Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96: 189-195. 6603515 [pii];10.1038/sj.bjc.6603515 [doi].
37. Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, et al. (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7: 496-501. 5624 [pii].
38. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955-3964. 10.1200/JCO.2003.08.092 [doi];JCO.2003.08.092 [pii].
39. Winkelmann S, Schaeffter T, Koehler T, Eggers H, Doessel O (2007) An optimal radial profile order based on the Golden Ratio for time-resolved MRI. IEEE Trans Med Imaging 26: 68-76. 10.1109/TMI.2006.885337 [doi]. (Pubitemid 46096351)
40. Aref M, Chaudhari AR, Bailey KL, Aref S, Wiener EC (2008) Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates. Magn Reson Imaging 26: 1279-1293. S0730-725X(08)00096-9 [pii];10.1016/j.mri.2008.02.015 [doi].
41. Steingoetter A, Svensson J, Kosanke Y, Botnar RM, Schwaiger M, et al. (2011) Reference region-based pharmacokinetic modeling in quantitative dynamic contract-enhanced MRI allows robust treatment monitoring in a rat liver tumor model despite cardiovascular changes. Magn Reson Med 65: 229-238. 10.1002/mrm.22589 [doi].
42. Jesberger JA, Rafie N, Duerk JL, Sunshine JL, Mendez M, et al. (2006) Model-free parameters from dynamic contrast-enhanced-MRI: sensitivity to EES volume fraction and bolus timing. J Magn Reson Imaging 24: 586-594. 10.1002/jmri.20670 [doi]. (Pubitemid 44320561)
43. Roberts C, Issa B, Stone A, Jackson A, Waterton JC, et al. (2006) Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 23: 554-563. 10.1002/jmri.20529 [doi].
44. Thoeny HC, De KF, Vandecaveye V, Chen F, Sun X, et al. (2005) Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237: 492-499. 2372041638 [pii];10.1148/radiol.2372041638 [doi].